2020
395 A first-in-human study of FS118, a tetravalent bispecific antibody targeting LAG-3 and PD-L1, in patients with advanced cancer and resistance to PD-(L)1 therapy
Yap T, Wong D, Hu-Lieskovan S, Papadopoulos K, Morrow M, Grabowska U, Gliddon D, Holz J, LoRusso P. 395 A first-in-human study of FS118, a tetravalent bispecific antibody targeting LAG-3 and PD-L1, in patients with advanced cancer and resistance to PD-(L)1 therapy. 2020, a240-a240. DOI: 10.1136/jitc-2020-sitc2020.0395.Peer-Reviewed Original ResearchFirst-in-human study of camidanlumab tesirine (ADCT-301, Cami), an anti-CD25 targeted therapy in patients (pts) with advanced solid tumours: Pharmacokinetics (PK) and biomarker evaluation
Puzanov I, Havenith K, Boni J, Cruz H, Anderson K, Kopotsha T, Le Bruchec Y, Bendell J, Kummar S, Papadopoulos K, LoRusso P, Wuerthner J. First-in-human study of camidanlumab tesirine (ADCT-301, Cami), an anti-CD25 targeted therapy in patients (pts) with advanced solid tumours: Pharmacokinetics (PK) and biomarker evaluation. Annals Of Oncology 2020, 31: s710-s711. DOI: 10.1016/j.annonc.2020.08.1150.Peer-Reviewed Original Research
2016
Safety, pharmacokinetics (PK), pharmacodynamics (Pd), and antitumor activity in a phase 1b study evaluating anti-ErbB3 antibody KTN3379 in adults with advanced tumors alone and with targeted therapies.
Falchook G, Bauer T, LoRusso P, McLaughlin J, LaVallee T, Peck R, Eder J. Safety, pharmacokinetics (PK), pharmacodynamics (Pd), and antitumor activity in a phase 1b study evaluating anti-ErbB3 antibody KTN3379 in adults with advanced tumors alone and with targeted therapies. Journal Of Clinical Oncology 2016, 34: 2501-2501. DOI: 10.1200/jco.2016.34.15_suppl.2501.Peer-Reviewed Original Research
2015
A phase 1, open-label study to evaluate the safety and pharmacokinetics of the anti ErbB3 antibody, KTN3379, alone or in combination with targeted therapies in patients with advanced tumors.
Bauer T, Infante J, Eder J, LoRusso P, LaVallee T, Gedrich R, Sidor C, Falchook G. A phase 1, open-label study to evaluate the safety and pharmacokinetics of the anti ErbB3 antibody, KTN3379, alone or in combination with targeted therapies in patients with advanced tumors. Journal Of Clinical Oncology 2015, 33: 2598-2598. DOI: 10.1200/jco.2015.33.15_suppl.2598.Peer-Reviewed Original Research
2010
Quantitative assessment of diagnostic markers and correlations with efficacy in two phase II studies of trastuzumab-DM1 (T-DM1) for patients (pts) with metastatic breast cancer (MBC) who had progressed on prior HER2-directed therapy.
LoRusso P, Krop I, Burris H, Vukelja S, Miller K, Zheng M, Chu Y, Lu M, Amler L, Rugo H. Quantitative assessment of diagnostic markers and correlations with efficacy in two phase II studies of trastuzumab-DM1 (T-DM1) for patients (pts) with metastatic breast cancer (MBC) who had progressed on prior HER2-directed therapy. Journal Of Clinical Oncology 2010, 28: 1016-1016. DOI: 10.1200/jco.2010.28.15_suppl.1016.Peer-Reviewed Original ResearchClinical responses to AZD6244 (ARRY-142886)-based combination therapy stratified by gene mutations in patients with metastatic melanoma.
Patel S, Lazar A, Mahoney S, Vaughn C, Gonzalez N, Papadopoulos N, Liu P, Infante J, LoRusso P, Kim K. Clinical responses to AZD6244 (ARRY-142886)-based combination therapy stratified by gene mutations in patients with metastatic melanoma. Journal Of Clinical Oncology 2010, 28: 8501-8501. DOI: 10.1200/jco.2010.28.15_suppl.8501.Peer-Reviewed Original Research
2007
Development of a functional assessment of side-effects to therapy (FAST) questionnaire to assess dermatology-related quality of life in patients treated with EGFR inhibitors (EGFRI): The FAST-EGFRI
Wagner L, Lai S, Aneja M, Lorusso P, Perez-Soler R, O’Brien B, Patel J, Lacouture M. Development of a functional assessment of side-effects to therapy (FAST) questionnaire to assess dermatology-related quality of life in patients treated with EGFR inhibitors (EGFRI): The FAST-EGFRI. Journal Of Clinical Oncology 2007, 25: 19532-19532. DOI: 10.1200/jco.2007.25.18_suppl.19532.Peer-Reviewed Original ResearchDisease-specific HRQL questionnairePatient self-report questionnairesHealth-related qualityBeneficial antitumor effectsEGFRI therapyDermatological toxicitiesHRQL questionnairesSkindex-29Self-report questionnairesAntitumor effectsBothersome aspectHRQLPatientsExpert cliniciansLife factorsHair alterationsQuestionnaireEGFRIsPruritusRashParonychiaTherapySymptomsCliniciansExpert input
2001
Analysis of skeletal-related events in breast cancer and response to therapy
LoRusso P. Analysis of skeletal-related events in breast cancer and response to therapy. Seminars In Oncology 2001, 28: 22-27. PMID: 11544572, DOI: 10.1016/s0093-7754(01)90228-3.Peer-Reviewed Original ResearchConceptsBone metastasesSkeletal morbiditySkeletal complicationsSkeletal related eventsTreatment of choiceBone painIntravenous pamidronateBisphosphonate treatmentSignificant morbidityCancer patientsPotent bisphosphonateStandard treatmentBone resorptionSurrogate markerClinical trialsCommon siteMetastatic cancerBreast cancerMorbidityMetastasisPatientsLife measurementsTherapyComplicationsPamidronate
1994
Randomized clinical trial of mitomycin-C with or without pretreatment with WR-2721 in patients with advanced colorectal cancer
Poplin E, LoRusso P, Lokich J, Gullo J, Leming P, Schulz J, Veach S, McCulloch W, Baker L, Schein P. Randomized clinical trial of mitomycin-C with or without pretreatment with WR-2721 in patients with advanced colorectal cancer. Cancer Chemotherapy And Pharmacology 1994, 33: 415-419. PMID: 8306416, DOI: 10.1007/bf00686271.Peer-Reviewed Original ResearchConceptsColorectal cancerMyelosuppressive potentialRefractory colorectal cancerMetastatic colorectal cancerAdvanced colorectal cancerRandomized clinical trialsUse of mitomycinRefractory colorectal carcinomaMitomycin therapyPlatelet nadirsHematologic toxicityPrincipal toxicityPartial responseClinical trialsColorectal carcinomaSame dosePatientsMitomycinCancerThrombocytopeniaTherapyToxicityGroupPretreatmentFluorouracil
1990
Antitumor efficacy of PD115934 (NSC 366140) against solid tumors of mice.
LoRusso P, Wozniak A, Polin L, Capps D, Leopold W, Werbel L, Biernat L, Dan M, Corbett T. Antitumor efficacy of PD115934 (NSC 366140) against solid tumors of mice. Cancer Research 1990, 50: 4900-5. PMID: 2165850.Peer-Reviewed Original ResearchMeSH KeywordsAcridinesAdenocarcinomaAnimalsAntineoplastic AgentsCarcinoma, Intraductal, NoninfiltratingCell SurvivalColonic NeoplasmsDrug Evaluation, PreclinicalDrug Screening Assays, AntitumorMiceMice, Inbred BALB CMice, Inbred C3HMice, Inbred C57BLMice, Inbred DBAMice, Inbred StrainsPancreatic NeoplasmsPyrazolesTumor Cells, CulturedConceptsInfusional therapyCentral nervous system toxicityNervous system toxicityDisk diffusionPreclinical toxicology evaluationColon adenocarcinoma 38Log cell killMain toxicityBolus therapySystem toxicityCellular cytotoxicityMurine L1210 leukemiaSolid tumorsInfusion studiesTotal doseCell killAntitumor efficacyHuman investigationsL1210 leukemiaAgar disk diffusionTherapySolid tumor selectivityTumor selectivityToxicology evaluationToxicity